Patents Assigned to Trustees of University of Pennsylvania
-
Patent number: 11970525Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).Type: GrantFiled: October 23, 2020Date of Patent: April 30, 2024Assignees: The Trustees of the University of Pennsylvania, Novartis AG, The Scripps Research InstituteInventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
-
Publication number: 20240131068Abstract: The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD19.Type: ApplicationFiled: October 17, 2023Publication date: April 25, 2024Applicants: Kite Pharma, Inc., The Trustees of the University of PennsylvaniaInventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
-
Publication number: 20240123068Abstract: The disclosure relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.Type: ApplicationFiled: October 18, 2023Publication date: April 18, 2024Applicants: Kite Pharma, Inc., The Trustees of the University of PennsylvaniaInventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
-
Publication number: 20240122594Abstract: The presently disclosed subject matter provides systems and methods for performing minimally invasive surgery. A laparoscopic device for performing minimally invasive surgery can include a mesh configured to be affixed to a fascial tissue to reinforce the fascial tissue. The mesh can be attached to the laparoscopic device before the mesh reaches the fascial tissue. The laparoscopic device can also include a telescoping arm configured to deliver the mesh to the fascial tissue. The telescoping arm can be further configured to position the mesh at the fascial tissue by releasing the mesh from the laparoscopic device.Type: ApplicationFiled: December 7, 2023Publication date: April 18, 2024Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: John P. Fischer, Rex Peters
-
Patent number: 11961283Abstract: Methods, systems, and computer readable media for model-based robust deep learning. In some examples, a method includes obtaining a model of natural variation for a machine learning task. The model of natural variation includes a mapping that specifies how an input datum can be naturally varied by a nuisance parameter. The method includes training, using the model of natural variation and training data for the machine learning task, a neural network to complete the machine learning task such that the neural network is robust to natural variation specified by the model of natural variation.Type: GrantFiled: June 3, 2021Date of Patent: April 16, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: George J. Pappas, Hamed Hassani, Alexander Robey
-
Patent number: 11958892Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.Type: GrantFiled: February 17, 2020Date of Patent: April 16, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
-
Publication number: 20240115740Abstract: This invention relates to the compositions and methods for labeling antibodies and other proteins and targeting agents with a helical bundle protein that is functionalized with cargo. Cargos can include but are not limited to fluorescent dyes, haptens (e.g. biotin), contrast agents (e.g. gadolinium, radionuclides), chelated metals, therapeutic agents, sensitizers, or other small molecules. Specifically, provided herein are compositions having a helical bundle, that has been labeled at precisely defined locations with cargo, and that can be conjugated, attached or fused to an antibody or other targeting agent.Type: ApplicationFiled: November 30, 2021Publication date: April 11, 2024Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, AlphaThera LLCInventors: Andrew TSOURKAS, Feifan YU
-
Publication number: 20240117322Abstract: A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine-glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.Type: ApplicationFiled: October 11, 2023Publication date: April 11, 2024Applicant: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Qiang Wang, April Tepe, Kevin Turner
-
Publication number: 20240117378Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.Type: ApplicationFiled: June 30, 2023Publication date: April 11, 2024Applicant: The Trustees of the University of PennsylvaniaInventors: Luk VANDENBERGHE, Guangping GAO, James M. WILSON
-
Patent number: 11950805Abstract: Disclosed are steerable needles having a shaft that can be controllably buckled, a steering head positioned at a distal end of the shaft, a transmission for controlling the orientation of the steering head, and a base at the end of the shaft, the base optionally comprising a controller for controlling the transmission. Also disclosed are methods of using the disclosed steerable needles.Type: GrantFiled: March 28, 2023Date of Patent: April 9, 2024Assignee: The Trustees of the University of PennsylvaniaInventor: Mark Yim
-
Publication number: 20240110190Abstract: Compositions and methods for treating fibrosis using oligonucleotide-based therapies are provided. These therapies can be used to increase expression of Bone morphogenetic protein receptor type II (BMPR2) via inhibition of upstream Open Reading Frames, thereby reducing vasoconstriction, vascular remodeling, and formation of fibrosis, particularly pulmonary arterial fibrosis related in patients in need thereof.Type: ApplicationFiled: February 28, 2022Publication date: April 4, 2024Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Yoseph BARASH, David Sheng Ming LEE, Louis R. GHANEM, Nicholas J. HAND
-
Patent number: 11946028Abstract: The presently disclosed subject matter provides a biomimetic organ model, and methods of its production and use. In one exemplary embodiment, the biomimetic organ model can be a multi-layer model including a at least two microchannels and at least one chamber slab with at least one membrane coated with cells disposed between at least one microchannel and the at least one chamber slab. In another exemplary embodiment, the biomimetic organ disease model can be a five-layer model including a first and second microchannel with a membrane-gel layer-membrane coated or encompassing cells disposed between the microchannels. In certain embodiments, at least one device can be coupled to the biomimetic organ model that delivers an agent to at least one microchannel.Type: GrantFiled: July 26, 2022Date of Patent: April 2, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Dongeun Huh, Mark Mondrinos
-
Patent number: 11938200Abstract: The present disclosure relates to magnetic resonance imaging (MRI) methods comprising (i) obtaining a baseline chemical exchange saturation transfer (CEST) MRI image of a patient, (ii) administering an effective amount of a non-nutritive sweetener to the patient, and (iii) obtaining one or more test CEST MRI image of the patient subsequent to the administering step (ii); wherein the step (i) and (iii) acquisition parameters are substantially the same. The non-nutritive sweetener may include a natural or artificial sugar alcohol, polyol, or combinations or derivatives thereof.Type: GrantFiled: February 3, 2017Date of Patent: March 26, 2024Assignees: The Trustees of the University of Pennsylvania, Sidra MedicineInventors: Ravinder Reddy, Mohammad Haris, Hari Hariharan, Puneet Bagga, Francesco M. Marincola, Mitchell D. Schnall
-
Patent number: 11939672Abstract: A nanoscale plate structure includes base plates and rib plates with nanoscale thickness and macroscopic lateral dimensions. The base plate resides in the first plane, the ribs can reside out-of-plane and form at least one strengthening rib, and additional base plates can reside in planes parallel to the first plane. The strengthening rib can be patterned such that there is no straight line path extending through a lateral dimension of the plate structure that does not intersect the at least one base plate and the at least one strengthening rib. The plates and ribs used in the structure have a thickness between about 1 nm and about 100 nm. The plate structures can be fabricated using a conformal deposition method including atomic layer deposition.Type: GrantFiled: December 3, 2021Date of Patent: March 26, 2024Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Igor Bargatin, Keivan Davami
-
Patent number: 11931380Abstract: The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders.Type: GrantFiled: April 14, 2021Date of Patent: March 19, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Steven M. Albelda, Liang-Chuan Wang, Gary Koretzky, Matthew Riese
-
Publication number: 20240082361Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.Type: ApplicationFiled: February 14, 2023Publication date: March 14, 2024Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, The Children's Hospital of PhiladelphiaInventors: Doris STOFFERS, Diva D. DE LEON, Charles STANLEY
-
Patent number: 11925466Abstract: An electrode, the electrode including an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A device, the device including a plurality of electrodes, each of the plurality of electrodes comprising an exposed contact surface, the exposed surface comprising a contact material, the contact material comprising a MXene. A method, the method including delivering electrical stimulation to a subject with an electrode that comprises an exposed contact surface, the exposed contact surface comprising a contact material that includes a MXene.Type: GrantFiled: September 14, 2018Date of Patent: March 12, 2024Assignees: The Trustees of the University of Pennsylvania, Drexel UniversityInventors: Flavia Vitale, Brian Litt, Nicolette Driscoll, Yury Gogotsi, Babak Anasori, Kathleen Maleski
-
Patent number: 11925685Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.Type: GrantFiled: September 19, 2017Date of Patent: March 12, 2024Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Karuppiah Muthumani, Jian Yan
-
Patent number: 11925662Abstract: The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.Type: GrantFiled: December 15, 2020Date of Patent: March 12, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Evgeniy Eruslanov, Steven Albelda
-
Patent number: 11918586Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1 X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituType: GrantFiled: March 26, 2021Date of Patent: March 5, 2024Assignees: TORQUR AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils